Kriya acquires gene therapy startup for undisclosed sum; Compugen wins milestone payment from AstraZeneca
Shankar Ramaswamy’s Kriya Therapeutics secured a buyout for an unknown amount Wednesday morning.
Kriya acquired privately held Redpin Therapeutics, which is developing gene therapies for the nervous system, the companies announced. According to a press release, the buyout serves as a “foundation” for Kriya’s neurology portfolio. The pair did not say how much it took to buy Redpin.
“Redpin’s innovative chemogenetics platform has the potential to transform the lives of patients suffering from intractable neurological conditions,” Ramaswamy, Kriya’s CEO, said in the release. “We are looking forward to integrating Redpin’s platform and pipeline into Kriya’s gene therapy engine.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.